title: SLIT: indications, follow-up, and management.
abstract: Specific sublingual immunotherapy (SLIT) has been proved to be a safe and effective approach in respiratory allergy. However, further research is required on aspects such as patient selection, use of optimal dosing, effects on asthma, long-term effects, and management of adverse reactions. In addition, the widely heterogeneous nature of studies on SLIT performed to date and the application of the criteria for subcutaneous immunotherapy make it difficult for the prescribing clinician to draw accurate and useful conclusions. Therefore, the QUASAR Group (QUality in the Administration of SLIT in Allergic Rhinitis), which comprises allergologists with broad clinical experience in SLIT, investigated the latest research findings and available data on this approach. Working parties were formed in 3 different categories: selection of candidates for SLIT, treatment efficacy, and adverse reactions. We performed a PubMed search for articles that were representative of each category and found 850. From these, we finally selected 266 articles, which were reviewed to retrieve data on SLIT. Evidence for each clinical question was graded according to the Oxford classification. The resulting text was evaluated on 3 occasions by all the members of the group until the final version was agreed upon. In this version, we review available evidence on SLIT, particularly with pollens, which is the subject of most articles. In areas where evidence is insufficient, an alternative agreed upon by the members of the QUASAR group is presented. Finally, we propose algorithms for selecting candidates for SLIT and for management of adverse events.
authors.forename: I
authors.initials: I
authors.lastname: Dávila
authors.forename: A
authors.initials: A
authors.lastname: Navarro
authors.forename: J
authors.initials: J
authors.lastname: Domínguez-Ortega
authors.forename: A
authors.initials: A
authors.lastname: Alonso
authors.forename: D
authors.initials: D
authors.lastname: Antolín-Amérigo
authors.forename: M C
authors.initials: MC
authors.lastname: Diéguez
authors.forename: E
authors.initials: E
authors.lastname: González-Mancebo
authors.forename: C
authors.initials: C
authors.lastname: Martíns
authors.forename: C
authors.initials: C
authors.lastname: Martínez
authors.forename: B
authors.initials: B
authors.lastname: Núñez
authors.forename: N
authors.initials: N
authors.lastname: Prior
authors.forename: M
authors.initials: M
authors.lastname: Rechel
authors.forename: A
authors.initials: A
authors.lastname: Rosado
authors.forename: J
authors.initials: J
authors.lastname: Ruiz-Hornillos
authors.forename: A
authors.initials: A
authors.lastname: Sansosti
authors.forename: M
authors.initials: M
authors.lastname: Torrecillas
authors.forename: M J
authors.initials: MJ
authors.lastname: Jerez
mesh_terms: D001249:Asthma / Q000628:therapy; D005500:Follow-Up Studies; D005512:Food Hypersensitivity / Q000628:therapy; D006801:Humans; D018579:Patient Selection; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000628:therapy; D063729:Sublingual Immunotherapy / Q000009:adverse effects / Q000379:methods